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diversegoals, andbenefit hasbeenalmost
universally reported. The benefit, how-
ever, has also been universally modest.
The relatively modest effects of cell re-
placement strategies undoubtedly stem
from the fact that these approaches are
currently employed with insufficient un-
derstanding of the mechanisms underly-
ing their observed benefit. Replacement
of lost cells likely plays an important
role, but functional improvement has
also been seen in the absence of this
effect. This has raised the possibility that
transplanted cells may secrete trophic
factors, or optimize the postinjury envi-
ronment, in order to facilitate neuropro-
tection or enhanced plasticity of surviving,
endogenous cells (Ourednik and Oured-
nik, 2004; Shetty and Turner, 2000). One
must also consider that different donor
cell types may lead to beneficial out-
comes through distinct mechanisms.
Studies exploring these possibilities are
critically needed to advance the field of
spinal repair. With improved understand-
ing of the biology of transplanted cells
and their interaction(s) with the host
CNS, it may be possible to alter the exog-
enous cells and/or host environment in
order to augment functional recovery.
Enhanced knowledge of neural stem
cell biology, such as the advances pro-
vided by Meletis et al. (2008), will be key
to using neural precursor cells for CNS
repair and regeneration. Also key will be
an increased understanding of the sig-
naling pathways that underlie the differen-
tiation of neural stem cells, as recently
described by Whittemore’s group (Cheng
et al., 2007).
In conclusion, the work by Meletis et al.
(2008) represents an important step for-
ward in understanding the biology of en-
dogenous neural stem cells in the CNS.
It is fascinating to consider that the cells
at the center of the spinal cord may play
a central role in its repair.
REFERENCES
Adrian, E.K., and Walker, B.E. (1962). J. Neuro-
pathol. Exp. Neurol. 21, 597–609.
Baptiste, D.C., and Fehlings, M.G. (2008). Expert
Opin. Emerg. Drugs 13, 63–80.
Cheng, X., Wang, Y., He, Q., Qiu, M., Whittemore,
S.R., and Cao, Q. (2007). Stem Cells 25, 3204–
3214.
Hofstetter, C.P., Holmstro¨m, N.A., Lilja, J.A.,
Schweinhardt, P., Hao, J., Spenger, C., Wie-
senfeld-Hallin, Z., Kurpad, S.N., Frise´n, J.,
and Olson, L. (2005). Nat. Neurosci. 8, 346–
353.
Karimi-Abdolrezaee, S., Eftekharpour, E., Wang,
J., Morshead, C.M., and Fehlings, M.G. (2006).
J. Neurosci. 26, 3377–3389.
Meletis, K., Barnabe´-Heider, F., Carle´n, M., Everg-
ren, E., Tomilin, N., Shupliakov, O., and Frise´n, J.
(2008). PLoS Biol. 6, e182. 10.1371/journal.pbio.
0060182.
Namiki, J., and Tator, C.H. (1999). J. Neuropathol.
Exp. Neurol. 58, 489–498.
Ourednik, V., and Ourednik, J. (2004). J. Neurosci.
Res. 76, 193–204.
Rossignol, S., Schwab, M., Schwartz, M., and
Fehlings, M.G. (2007). J. Neurosci. 27, 11782–
11792.
Shetty, A.K., and Turner, D.A. (2000). J. Neurosci.
20, 8788–8801.
Cell Stem Cell
PreviewsTurning Back Time: Reversing Tissue
Pathology to Enhance Stem Cell Engraftment
Thomas A. Rando1,*
1Department of Neurology and Neurological Sciences, Stanford University School of Medicine and VA Palo Alto Health Care Systems,
Stanford, CA 94305-5235, USA
*Correspondence: rando@stanford.edu
DOI 10.1016/j.stem.2008.08.006
Histopathologic changes in diseased tissues may render them inhospitable to engraftment by transplanted
stem cells. A recent report in Nature Medicine (Gargioli et al., 2008) demonstrates that pretreatment of
dystrophic mouse muscles with tissue-modifying factors leads to reduced fibrosis, increased vascularity,
and enhanced stem cell engraftment.Stem cell transplantation holds great
promise for the treatment of degenerative
diseases. The success of stem cell trans-
plantation depends not only the intrinsic
properties of the transplanted cells, but
also on the properties of the tissue into
which the cells will be introduced. It
seems to be generally true that exoge-
nous stem cells engraft farmore efficiently
into tissues, whether normal or diseased,232 Cell Stem Cell 3, September 11, 2008 ª2from which endogenous stem cells have
been depleted. This has led to the con-
cept that exogenous cells require a
‘‘vacated niche’’ for effective engraftment
(Scadden, 2006). However, diseased tis-
sues may pose specific barriers to cell
transplantation. If the exogenous cells
are introduced into an environment of
necrosis, inflammation, and degenerative
changes, their ability to engraft, prolifer-008 Elsevier Inc.ate, and differentiate into mature tissue
may be severely compromised. In the
muscular dystrophies, a group of dis-
eases for which stem cell transplantation
has long been considered as a poten-
tial therapeutic modality (Partridge and
Sloper, 1977), the host environment is
particularly relevant. The dystrophies are
characterized by a progressive replace-
ment of normal skeletal muscle with
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sue (Emery, 2002). Therefore, any myo-
genic stem cells delivered to the muscle
by direct injection are likely to face an
extremely inhospitable environment in
which to make new muscle. Furthermore,
concomitant with the degenerative
changes is a decline in the vascularity of
the tissue, thereby diminishing the poten-
tial of using a vascular route for delivering
stem cells to muscles throughout the
body. In sum, the histologic features of
dystrophic muscle pose substantial bar-
riers to stem cell therapeutics for these
diseases.
In a recent paper in Nature Medicine,
Gargioli, Cossu, and colleagues (Gargioli
et al., 2008) present a novel approach to
deal with the problems of the dystrophic
histopathology prior to the vascular deliv-
ery of myogenic stem cells. The rationale
of the approach is several-fold, but the
most important concept is that the deliv-
ery of factors that degrade extracellular
matrix and promote angiogenesis might
reduce fibrosis and enhance vasculariza-
tion, respectively, thereby rendering the
tissuemore amenable to subsequent vas-
cular delivery and engraftment of exoge-
nous stem cells. To reduce fibrosis, the
authors chose matrix metalloproteinase
9 (MMP-9); to enhance vascularization,
they chose placenta growth factor
(PIGF). However, they did not just inject
these factors into muscle. Rather, they
engineered tendon fibroblasts to produce
each of the factors. They then injected
those fibroblasts into a specific hindlimb
muscle of mice with amuscular dystrophy
due to a-sarcoglycan deficiency. Tendon
fibroblasts were chosen both because
they may be a readily available cell popu-
lation from patients (since patients with
muscular dystrophies commonly undergo
surgical procedures to relieve tendon
contractions) and because they may be
relatively resistant to hypoxia as they nor-
mally reside in an avascular tissue (Web-
ster and Burry, 1982). The latter feature
was considered important because cells
injected as a bolus into skeletal muscle
need to survive initially as an avascular
mass, in addition to the fact that the dys-
trophic muscle is already hypovascular,
as noted.
Following transplantation of the genet-
ically modified fibroblasts, the investi-
gators examined their effects on tissue
pathology. Indeed, various indices of fi-brosis declined and indices of vascularity
increased when muscles were injected
with both MMP-9-producing and PIGF-
producing fibroblasts, with almost no
benefit from the injection of either fibro-
blast population alone. Surprisingly, fibro-
blasts producing MMP-9 had little effect
on fibrosis and fibroblasts producing
PIGF had little effect on vascularity, but
the combination showed substantial
improvement in both measures. Clearly,
there must be some synergistic actions
of the two factors within the context of
the physiology of the dystrophic muscle.
Having established conditions for re-
versing aspects of the dystrophic pathol-
ogy, the investigators proceeded to test
the efficacy of stem cell engraftment in
the pretreated muscles. The authors
chose to deliver a wild-type (i.e., a-sarco-
glycan+) population of myogenic progeni-
tors, termed ‘‘mesoangioblasts,’’ by intra-
arterial injection because these cells
efficiently cross vascular boundaries and
colonize muscle (Minasi et al., 2002).
They then examined muscles at different
times after intra-arterial mesangioblast in-
jections for various measures of engraft-
ment and therapeutic response. As with
the measures of histopathology, pretreat-
ment with either population of genetically
engineered fibroblasts alone had negligi-
ble effect on the transplantation efficacy,
but pretreatment with both populations
led to an increase in the amount of a-sar-
coglycan expression and an increase in
new muscle formation. Perhaps the most
surprising and intriguing finding was that
an enhancement of transplantation effi-
cacy was observed not only in the specific
muscle pretreated with the genetically
engineered fibroblasts, but also in other
muscles in the limb, including muscles
quite distant from the treated muscles.
This was perhaps related to the finding
that, despite the fact that the fibroblasts
were directly injected into only one mus-
cle, some low level spread of the cells
and diffusion of the factors to other mus-
cles of the limb were observed.
These specific findings may shed light
on the nature of the observed synergy be-
tween MMP-9 and PIGF treatment. It may
be that the ability of PIGF to promote
angiogenesis requires a regression of the
tissue fibrosis, as promoted by MMP-9.
This possibility would be consistent with
the finding that neither factor alone is
sufficient to promote mesoangioblastCell Stem Cell 3, Sengraftment, given that PIGF would not
effectively promote angiogenesis without
concomitant matrix remodeling, and
MMP-9 obviously would not promote
increased vascularity on its own. This
model of synergywould also imply a requi-
site temporal sequence andwould predict
MMP-9 treatment followed by PIGF treat-
ment would be most successful, whereas
the reverse would be ineffective.
These results are very encouraging and
reflect a growing interest not only in the
optimal characteristics of stem cells and
progenitors for therapeutic transplanta-
tion, but also in the host environment
into which those cells may be trans-
planted (Gopinath and Rando, 2008).
Consideration of the environment of dis-
eased tissues may present an apparent
paradox. On the one hand, the disease it-
self may render the tissue more amenable
to stem cell therapy if the pathogenetic
process results in a diminution of the en-
dogenous stem cell population, resulting
in vacated stem cell niches. On the other
hand, the disease process may also ren-
der the tissue refractory to stem cell ther-
apy by engendering pathologic changes
that resist exogenous stem cell engraft-
ment. Recent studies have shed new light
on the cellular andmolecular mechanisms
by which fibrotic and adipogenic changes
arise in aged skeletal muscle (Brack et al.,
2007; Hidestrand et al., 2008), revealing
potential approaches to the prevention
of these changes. Similar mechanisms
may underlie the age-dependent fibro-
genesis and adipogenesis that occur in
the dystrophies. The use of antifibrotic
therapy in the muscular dystrophies is in
early stages of investigation but holds
promise (Andreetta et al., 2006). The re-
sults of the studies by Gargioli et al. pro-
vide further evidence in support of the
idea that optimization of the recipient tis-
sue may be just as important as optimiza-
tion of the stem cells that will be delivered
(Gargioli et al., 2008). Using intramuscular
injection of genetically-modified fibro-
blasts to deliver tissue-modifying factors
may not be optimal for clinical applica-
tions in humans because of the complex-
ity thiswould add to the already significant
challenges of stem cell transplantation
itself. However, this approach represents
a proof-of-principle and also offers a start-
ing point for comparison of various treat-
ments of diseased tissues designed to
enhance stem cell engraftment.eptember 11, 2008 ª2008 Elsevier Inc. 233
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A trio of studies in this issue of Cell
dimensional imaging techniques t
Combined, the results also provide
Adult NSCs arise from radial glia within
the subventricular zone (SVZ) of the lateral
ventricles (Merkle et al., 2004), one of two
regional concentrations of NSCs in the
brain that include the dentate gyrus sub-
granular zone (Alvarez-Buylla and Lim,
2004). Although the potency of NSCs ren-
ders them an attractive resource in the
hunt for cures of neurodegenerative dis-
eases, the mechanisms that control the
behavior of these cells remain largely
unknown.
Similar to other tissue-specific stem
cells, NSCs are presumed to exist in
specializedmicroenvironments, or niches,
that regulate their function. Thus, a better
understanding of the architecture of the
ependymal layer and SVZ could yield
important insights into the mechanisms
that regulate NSCs; however, a clear
view of the complex three-dimensional
arrangement of blood vessels, cell pro-
cesses, and extracellular matrix (ECM)
proteins found in this region of the brain
is lost among the thin tissue sections
processed using conventional histologic
approaches. Therefore, three studies in
this issue have used novel whole-mount
imaging techniques to provide the first
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Stem Cell from Mirzadeh et al., Shen
o reveal microanatomical details of
a framework for future functional stu
high-resolution, three-dimensional de-
scriptions of the adult NSC niche.
Tavazoie et al. (2008) and Shen et al.
(2008) focused their studies on the cellular
and molecular interactions surrounding
the SVZ vasculature, since emerging evi-
dence has suggested that blood vessels
are key components of tissue-specific
stem cell niches (Palmer et al., 2000;
Shen et al., 2004; Yoshida et al., 2007).
Using glial fibrillary acidic protein-green
fluorescence protein (GFAP-GFP) trans-
genic reporter mice, they demonstrate
that the SVZ vasculature includes an ex-
tensive, superficial network of planar in-
terconnected blood vessels that spans
the entire SVZ, just beneath the ependy-
mal layer. Their studies demonstrate that
GFAP+/LeX+ BrDU-retaining NSCs inter-
act closely with these vessels, an intimate
relationship that Shen and colleagues
report Type A neuroblasts retain as they
migrate from theSVZ to the olfactory bulb.
A noteworthy insight provided by these
studies and those of Mirzadeh et al.
(2008) is the demonstration that adult
NSCs, similar to their radial glial fore-
bears, are highly polarized, contacting
the ventricle through a short apical pro-
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cess and a blood vessel through a long
basal process. Indeed, Mirzadeh et al.
(2008) show that these basal processes
contribute to the gliotubes that seem to
guide migrating neuroblasts, much as ra-
dial glial fibers guide neuroblasts up to the
developing cortical plate. Although adult
NSCs have been shown to arise from ra-
dial glia (Merkle et al., 2004), and neuro-
genic radial glia have been identified in
the adult songbird brain, the data con-
tained in this issue of Cell Stem Cell sug-
gest that mammalian radial glia progeni-
tors establish critical structure-function
relationships within the niche that are
inherited by adult NSCs.
A close interaction between SVZ NSCs
and blood vessels might be expected in
light of similar cell-cell interactions in the
hippocampus (Palmer et al., 2000); how-
ever, data from Tavazoie et al. provide
the first evidence that these sites of
neurovascular interaction have functional
significance in vivo. They show that
NSC-vessel contacts in the SVZ are un-
usually permeable and frequently devoid
of astrocytic endfeet or a pericyte sheath
(features of the blood-brain barrier that
minimize access of neural cells to
